Cardioprotection thread, page-687

interesting stuff, seems to be protective using receptor and anti cancer RAS inhibitor mechanism.

No expert but although a currently approved product it’s for blood pressure control, to be used for cancer and in combo with dox would require trials, so being first to market is relevant. Off-label use wouldn’t be a feasible strategy.

RAS inhibitor may be selective and promising anti-cancer in certain cancer indications, you can see the two groups below one performing well and group B (perhaps not impacted by RAS) which was underwhelming anti-cancer and x100 dose of Bisantrene.

Included Bisantrene as a comparative, note the IC50
dosing.



http://dx.doi.org/10.1177/1470320319851310